Ardsley Advisory Partners bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, Holdings Channel reports. The institutional investor bought 12,500 shares of the biotechnology company’s stock, valued at approximately $380,000.
Several other institutional investors have also recently added to or reduced their stakes in EXEL. Dimensional Fund Advisors LP raised its position in Exelixis by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 620,096 shares of the biotechnology company’s stock valued at $15,273,000 after acquiring an additional 28,195 shares in the last quarter. Aperio Group LLC raised its position in Exelixis by 8.9% during the third quarter. Aperio Group LLC now owns 63,557 shares of the biotechnology company’s stock valued at $1,540,000 after acquiring an additional 5,212 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in Exelixis during the third quarter valued at approximately $236,000. Crossmark Global Holdings Inc. purchased a new position in Exelixis during the third quarter valued at approximately $239,000. Finally, Swiss National Bank raised its position in Exelixis by 0.5% during the third quarter. Swiss National Bank now owns 489,200 shares of the biotechnology company’s stock valued at $11,853,000 after acquiring an additional 2,300 shares in the last quarter. 80.55% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on EXEL. BidaskClub cut Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday. Cann reiterated a “buy” rating and set a $40.00 price target on shares of Exelixis in a research report on Thursday, March 8th. Stifel Nicolaus lifted their price target on Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. ValuEngine cut Exelixis from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Finally, Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $34.10.
Shares of Exelixis, Inc. (EXEL) opened at $24.82 on Tuesday. The company has a market capitalization of $7,340.00, a P/E ratio of 50.65, a PEG ratio of 1.29 and a beta of 1.96. Exelixis, Inc. has a 12-month low of $18.03 and a 12-month high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.12. The business had revenue of $120.10 million during the quarter, compared to analysts’ expectations of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.12 earnings per share. analysts forecast that Exelixis, Inc. will post 0.59 EPS for the current fiscal year.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.